艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ADC 艾格里房产

交易中 12-15 11:53:44 EST

71.76

+0.01

+0.01%

最高72.25	最低71.58	成交量16.29万
今开71.94	昨收71.75	日振幅0.93%
总市值82.47亿	流通市值77.76亿	总股本1.15亿
成交额1,171万	换手率0.15%	流通股本1.08亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"艾格里房产","latestPrice":71.755,"timestamp":1765817620849,"preClose":71.75,"halted":0,"volume":162860,"delay":0,"floatShares":108366822,"shares":114934390,"eps":1.712089,"marketStatus":"交易中","change":0.005,"latestTime":"12-15 11:53:44 EST","open":71.94,"high":72.25,"low":71.58,"amount":11711304.1293,"amplitude":0.009338,"askPrice":71.75,"askSize":80,"bidPrice":71.71,"bidSize":62,"shortable":3,"etf":0,"ttmEps":1.712089,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1765832400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":71.75,"dividendRate":0.042561,"preHourTrading":{"tag":"盘前","latestPrice":72.81,"preClose":71.75,"latestTime":"09:21 EST","volume":64,"amount":4613.83008,"timestamp":1765808473051},"postHourTrading":{"tag":"盘后","latestPrice":71.75,"preClose":71.75,"latestTime":"19:39 EST","volume":84227,"amount":6043288.593,"timestamp":1765586379736},"volumeRatio":0.327178,"impliedVol":0.1931,"impliedVolPercentile":0.152},"requestUrl":"/m/hq/s/ADC","defaultTab":"news","newsList":[{"id":"2590552722","title":"【券商聚焦】交银国际上调康宁杰瑞制药(09966)评级至买入 看好其ADC产品矩阵的巨大全球市场潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2590552722","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590552722?lang=zh_cn&edition=full","pubTime":"2025-12-11 09:06","pubTimestamp":1765415190,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，康宁杰瑞制药 HER2双抗ADC管线加速推进，糖基定点偶联平台持续验证：JSKN003正在进行/即将启动多项注册临床，包括2L HER2+ BC、≥2L HER2低表达BC、PROC和HER2+ CRC。JSKN016单药在TNBC中显示出优异疗效，并正在一项针对晚期NSCLC的Ib期研究中探索与卡铂、伏美替尼、及依沃西单抗等药物的联用方案，预计相关数据将于2026年公布。该机构看好公司ADC产品矩阵的巨大全球市场潜力，上调2025-27年收入预测3-8%、上调DCF目标价至13.0港元、上调评级至买入。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971330","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","09966"],"gpt_icon":0},{"id":"2590394122","title":"新股前瞻|布局TCE肿瘤疗法千亿蓝海，时迈药业能否博得市场青睐？","url":"https://stock-news.laohu8.com/highlight/detail?id=2590394122","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590394122?lang=zh_cn&edition=full","pubTime":"2025-12-09 13:05","pubTimestamp":1765256702,"startTime":"0","endTime":"0","summary":"近日，又一创新药企正式向港交所提交上市申请。在此背景下，作为一家专注于实体瘤TCE疗法、且具备多款全球前列临床管线的企业，时迈药业的上市进程亦自然备受瞩目。布局TCE疗法 四款创新药物处于临床阶段智通财经APP了解到，时迈药业目前仍处于临床研发阶段，并无产品商业化。根据时迈药业招股书披露，当前仅有两款用于实体瘤的TCE药物获得全球批准，市场存在大量空白，这为具备相关布局能力的创新药企提供了结构性机遇。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B66KJ199.SGD","LU0053666078.USD","BK4231","IE00B7SZL793.SGD","ORR","BK4187","BK4107","LU2487616109.SGD","L","CRS","BK4585","LU0963586101.USD","BK4006","BK4080","IE0031619046.USD","BK4588","ADC","LU2065731478.USD","IE00B19Z4B17.USD","LU0210528500.USD"],"gpt_icon":0},{"id":"2589289437","title":"ADC药物与PD-1/VEGF双抗联用再添案例 科伦博泰与Crescent达成双向授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2589289437","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589289437?lang=zh_cn&edition=full","pubTime":"2025-12-05 19:52","pubTimestamp":1764935561,"startTime":"0","endTime":"0","summary":"12月4日，科伦博泰（HK06990）与CrescentBiopharma,Inc.（一家纳斯达克上市公司，以下简称Crescent）共同宣布，双方已建立战略合作伙伴关系。科伦博泰方面将ADC药物（抗体偶联药物）SKB105在中国以外权利授权Crescent，并预计将获得最高超13亿美元的授权收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512053584015760.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512053584015760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1169589451.USD","PD","BK4080","BK4231","ADC","LU1169590202.USD","BK4023"],"gpt_icon":0},{"id":"2589448869","title":"港股异动 | 百奥赛图-B(02315)涨超3% 授权IDEAYA双抗ADC项目IDE034获FDA IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589448869","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589448869?lang=zh_cn&edition=full","pubTime":"2025-12-05 14:46","pubTimestamp":1764917191,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B涨超3%，截至发稿，涨2.84%，报31.86港元，成交1299.1万港元。IDEAYA预计将在2026年第一季度开始患者入组，初步评估B7H3和PTK7共表达的实体瘤类型，包括肺癌、结直肠癌、头颈癌及卵巢/妇科肿瘤。此外，IDEAYA计划探索IDE034与其PARG抑制剂IDE161的联合治疗策略，以增强疗效持续性，并计划在2026年上半年重要医学会议上分享更多支持PARG与TOP1 ADC联合治疗机制的数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02315","688796","BK4231","ADC","BK1161","BK4080","IND"],"gpt_icon":0},{"id":"2589865213","title":"ADC与PD-1红海之外，宝济药业如何找到生物医药的“第二增长曲线”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2589865213","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589865213?lang=zh_cn&edition=full","pubTime":"2025-12-05 13:33","pubTimestamp":1764912788,"startTime":"0","endTime":"0","summary":"而在ADC、PD-1等热门靶点赛道数百家企业拥挤厮杀，从临床入组速度到未来的市场定价无不白热化的竞争中，上海宝济药业股份有限公司选择了一条截然不同的差异化战略路径。与传统疗法相比，KJ103的革命性优势则在于其“快”。目前，其领先地位和临床价值已获得监管机构的高度认可。对于KJ017而言，其市场空间并不取决于自身的销量，而是与整个千亿级生物药市场的增长深度绑定，其商业模式堪称典型的“卖水人”逻辑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["399441","LU1169590202.USD","02659","ADC","BK4080","LU1169589451.USD","PD","161726","BK4023","BK4231"],"gpt_icon":1},{"id":"2588709367","title":"复宏汉霖PD-L1 ADC II期结果读出；*ST苏吴进入退市整理期｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2588709367","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588709367?lang=zh_cn&edition=full","pubTime":"2025-12-02 07:01","pubTimestamp":1764630081,"startTime":"0","endTime":"0","summary":"丨2025年12月2日星期二丨NO.1复宏汉霖PD-L1ADCII期结果读出11月26日，复宏汉霖发布公告表示将在ESMOAsia2025大会上公布多项药物的临床数据。亮点之一在于核心资产PD-L1ADC药物HLX43在宫颈癌领域的II期研究结果。点评：针对PD-L1ADC开发在研管线并不多，目前进度最快的是辉瑞的PF-08046054，已至临床III期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512023579600777.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512023579600777.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0060","600200","PD","BK4080","BK0012","BK0239","BK0188","BK4231","159938","BK0028","BK1515","BK1574","09939","BK1161","LU1169590202.USD","02696","LU1169589451.USD","BK4023","HK0000165453.HKD","ADC"],"gpt_icon":0},{"id":"2586389271","title":"兴证国际：首予映恩生物-B(09606)“增持”评级 公司立足创新持续引领下一代ADC研发浪潮","url":"https://stock-news.laohu8.com/highlight/detail?id=2586389271","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586389271?lang=zh_cn&edition=full","pubTime":"2025-11-28 09:08","pubTimestamp":1764292136,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，兴证国际发布研报称，首次覆盖，给予映恩生物-B“增持”评级，映恩生物聚焦 ADC 赛道领域，借助与 BioNTech 等全球领先药企的合作，以中国速度推进全球多中心临床快速布局，在 ADC 领域占据有利的竞争身位。兴证国际主要观点如下：近期事件2025 年 10 月 23 日公司举办研发日，介绍公司 ADC 产品管线近期进展以及未来发展方向。2025 年 11 月 14 日公司自身免疫 ADC 产品管线 DB-2304用于系统性红斑狼疮临床全球 1/2a期研究的 2a 期部分完成首例患者给药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374883.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","09606","06058"],"gpt_icon":0},{"id":"2586428185","title":"港股异动 | 中国生物制药(01177)涨超4% 旗下正大晴天自研HER2双抗ADC新辅助治疗乳腺癌取得重要突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2586428185","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586428185?lang=zh_cn&edition=full","pubTime":"2025-11-26 10:28","pubTimestamp":1764124108,"startTime":"0","endTime":"0","summary":"消息面上，11月25日，注射用TQB2102单药用于HER2阳性乳腺癌新辅助治疗的Ⅱ期临床研究结果，获国际著名期刊《临床肿瘤学杂志》 在线发表。TQB2102是中国生物制药旗下正大天晴自主研发的一种靶向HER2两个非重叠表位ECD2及ECD4的抗体偶联药物。该项研究由复旦大学附属肿瘤医院邵志敏教授团队领衔，为首个证实双表位HER2 ADC TQB2102在乳腺癌新辅助治疗阶段具有良好疗效和安全性的研究，Ⅲ期注册临床研究正在开展中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","HK0000165453.HKD","IE00BZ08YT58.USD","BK1521","IE00BZ08YR35.GBP","BK4080","BK4231","BK1515","IE00BZ08YS42.EUR","01177","BK1191","ADC"],"gpt_icon":0},{"id":"2586341050","title":"港股异动 | 和铂医药-B(02142)涨近5% 与阿斯利康进一步拓展合作范围 开发ADC及T细胞衔接器疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2586341050","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586341050?lang=zh_cn&edition=full","pubTime":"2025-11-25 10:23","pubTimestamp":1764037381,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B(02142)涨近5%，截至发稿，涨4.92%，报13.62港元，成交额1542.11万港元。消息面上，11月24日，和铂医药-B发布公告，有关公司的间接全资附属公司和铂医药(上海)有限责任公司(和铂上海)与AstraZeneca PLC (AstraZeneca)订立合作、选择权及许可协议，于2025年11月24日，经修订和铂上海与 AstraZeneca订立的合作协议后，订约双方的合作范围进一步扩展，旨在结合两家公司的专业知识，共同发现及开发包括抗体偶联药物(ADC)及T细胞衔接器在内的新一代生物疗法。经济条款与合作协议项下建立的财务框架仍然一致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","BK1583","LU2236285917.USD","BK4568","BK1574","LU1829250122.USD","BK4585","BK4231","LU0889565916.HKD","LU0320765992.SGD","LU2456880835.USD","LU2462157665.USD","BK4080","BK4588","LU0109394709.USD","BK1161","BK4007","LU2417539215.USD","AZN","02142"],"gpt_icon":0},{"id":"2585631430","title":"和铂医药-B与 AstraZeneca修订合作协议 合作范围进一步扩展","url":"https://stock-news.laohu8.com/highlight/detail?id=2585631430","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585631430?lang=zh_cn&edition=full","pubTime":"2025-11-24 08:05","pubTimestamp":1763942700,"startTime":"0","endTime":"0","summary":"和铂医药-B(02142)公布，有关公司的间接全资附属公司和铂医药(上海)有限责任...和铂医药-B(02142)公布，有关公司的间接全资附属公司和铂医药(上海)有限责任公司(和铂上海)与AstraZeneca PLC (AstraZeneca)订立合作、选择权及许可协议，于2025年11月24日，经修订和铂上海与 AstraZeneca订立的合作协议后，订约双方的合作范围进一步扩展，旨在结合两家公司的专业知识，共同发现及开发包括抗体偶联药物(ADC)及T细胞衔接器在内的新一代生物疗法。经济条款与合作协议项下建立的财务框架仍然一致。追加内容本文作者可以追加内容哦 !","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124080807977b515f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124080807977b515f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","BK4585","LU2417539215.USD","LU2462157665.USD","BK4080","BK4568","ADC","BK4007","BK4588","AZN","LU0109394709.USD","LU0889565916.HKD","LU1829250122.USD","LU2236285917.USD","LU2456880835.USD","BK4231"],"gpt_icon":0},{"id":"2584135516","title":"智通港股解盘 | 券商收购合并再起 传闻引发地产走强","url":"https://stock-news.laohu8.com/highlight/detail?id=2584135516","media":"智通财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584135516?lang=zh_cn&edition=full","pubTime":"2025-11-20 19:27","pubTimestamp":1763638024,"startTime":"0","endTime":"0","summary":"隔夜，美联储发布10月议息会议纪要。纪要显示，在这次最终决定降息的会议上，美联储委员\"分歧严重\"。关键时刻出现利好传闻，知情人士称中国正考虑采取新措施，来扭转房地产市场低迷情势。不过这只是传闻，并未获得证实。此外，有行业厂商目前仍分批对不同覆铜板产品价格进行调整。2025H1，公司总收入74.34亿元，同比增长14.3%；归母净利润为31.35亿元，同比增长15.02%。阿美替尼作为国产首款三代EGFRTKI，销售增长迅速，适应症持续拓展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1371717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1989772923.USD","02577","01109","3NVD.UK","LNNGY","01359","01635","01729","01918","02631","03988","NVDD","IE0004086264.USD","03323","LU2111349929.HKD","82331","01988","01880","LU0786609619.USD","NVDS","NVD2.UK","00688","NVDS.UK","ADC","01888","03121","NVDX","02423","02331","NVIW.SI","00914","NVD","LU1328615791.USD","06978","NVD3.UK","03692","01658","BK4587","00148","LU2236285917.USD","NVDU","SNVD.UK","SG9999002232.USD","2NVD.UK","03896","03143","NVDY"],"gpt_icon":1},{"id":"2584979211","title":"开发下一代 ADC，新锐融资1.2亿美元，默沙东支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2584979211","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584979211?lang=zh_cn&edition=full","pubTime":"2025-11-19 22:12","pubTimestamp":1763561520,"startTime":"0","endTime":"0","summary":"Solve Therapeutics，一家开发实体瘤ADC药物的生物技术公司，宣布完成1.2亿美元超额认购融资，此轮融资由Yosemite领投，Alexandria Venture Investments、默沙东等多家机构参投，未提及财务顾问。该公司由行业资深领导者于2021年创立，已累计融资3.21亿美元。其核心技术CloakLink旨在增强ADC药物血浆稳定性，改善药代动力学，降低毒性。主要项目SLV-154和SLV-324正在进行I期临床试验，配备新诊断方法以实现精确患者选择。最新融资将用于加速临床管线和专有CloakLink连接子平台开发，支持两个项目的Ib期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120014629a4ad5af9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120014629a4ad5af9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4550","LU1699723380.USD","SG9999002232.USD","LU1069347547.HKD","LU0234572021.USD","LU1066051811.HKD","LU0861579265.USD","LU0058720904.USD","LU1989771016.USD","IE0009355771.USD","LU1066051225.USD","MRK","SG9999014567.USD","LU0208291251.USD","LU1430594728.SGD","LU1917777945.USD","LU2023250843.SGD","LU0098860793.USD","IE00BLSP4452.SGD","SG9999002224.SGD","SG9999014542.SGD","IE00B2B36J28.USD","LU0320765646.SGD","LU0266013472.USD","LU0320765489.SGD","BK4533","LU1023059063.AUD","BK4534","LU1035773651.USD","IE00BFTCPJ56.SGD","LU1941712348.USD","LU1934455863.HKD","LU0211331839.USD","LU2361044949.HKD","LU0265550946.USD","LU1585245621.USD","BK4588","ADC","LU1974910355.USD","LU2112291526.USD","LU0203345920.USD","SG9999015341.SGD","LU1929549753.HKD","IE000M9KFDE8.USD","BK4559","LU2361045086.USD","LU2361044865.SGD","LU0070302665.USD","SG9999015358.SGD","SGXZ57979304.SGD"],"gpt_icon":0},{"id":"2584938632","title":"中国生物制药(01177)：LM-350“CDH17 ADC”临床试验申请获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2584938632","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584938632?lang=zh_cn&edition=full","pubTime":"2025-11-18 17:36","pubTimestamp":1763458582,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团全资附属公司礼新医药科技(上海)有限公司自主研发的国家1类创新药LM-350“CDH17抗体偶联药物”已获得中国国家药品监督管理局的临床试验批准。LM-350是基于礼新医药新一代LM-ADC平台开发的一款靶向CDH17的ADC，能够高度选择性地结合CDH17，具有很强的内化能力。LM-350采用IgG1野生型构型，同时具备抗体依赖细胞介导的细胞毒性作用活性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YR35.GBP","BK1521","IE00BZ08YT58.USD","ADC","01177","BK4080","IE00BZ08YS42.EUR","HK0000165453.HKD","BK1515","BK1589","BK1191","BK4231"],"gpt_icon":0},{"id":"2584606853","title":"攻克耗能黑洞，下一代AI硬件系统能耗锐减57.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584606853","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584606853?lang=zh_cn&edition=full","pubTime":"2025-11-18 08:41","pubTimestamp":1763426497,"startTime":"0","endTime":"0","summary":"在先进的存算一体芯片中，ADC的能耗占比高达87.8%，面积占比高达75.2%，成为限制CIM芯片性能的关键因素。研究团队忆阻器ADC方案，通过存算一体化与忆阻器硬件创新，实现了AI硬件能耗锐减57.2%的技术突破。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.jrj.com.cn/2025/11/18084154249325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jrj_jhqb","symbols":["CIM","BK4080","BK4585","ADC","BK4588","BK4231","BK4543","BK4110","BK4551","BK4587","BK4023","BK4528"],"gpt_icon":1},{"id":"2584629325","title":"睿智医药发布全球首台ADC和核苷酸单体药物智造系统","url":"https://stock-news.laohu8.com/highlight/detail?id=2584629325","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584629325?lang=zh_cn&edition=full","pubTime":"2025-11-17 21:40","pubTimestamp":1763386801,"startTime":"0","endTime":"0","summary":"11月17日，“超限·智造——ADC和核苷酸单体药物智造系统发布会”在上海张江举行。睿智医药联合华东师范大学推出全球首台适用于ADC与核苷酸亚磷酰胺单体合成的药物智造系统，为创新药产业高质量发展注入关键动能。据介绍，此次发布的ADC药物智造系统TAO-AG1采用微流控与AI智能控制技术，体积仅480×390×500mm，实现空间的高效利用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251117/31802762.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0216","BK0077","BK4231","ADC","BK4080","300149"],"gpt_icon":0},{"id":"2583289945","title":"港股上市七个月，映恩生物启动回A计划 上半年亏逾20亿元，创始人高年薪受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2583289945","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583289945?lang=zh_cn&edition=full","pubTime":"2025-11-14 11:33","pubTimestamp":1763091188,"startTime":"0","endTime":"0","summary":"在港股上市七个月后，映恩生物（证券简称：映恩生物-B；代码：09606）又拟回A股科创板上市。今年10月公司港交所公告称，公司拟发行将于上海证券交易所科创板上市并以人民币买卖的普通股。据证监会官网近日消息，映恩生物上周已正式启动上市辅导，中信证券担任辅导机构。官网资料显示，映恩生物是一家临床阶段的创新生物药企，专注于为癌症和自身免疫性疾病患者研发新一代抗体偶联药物（ADC）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511143564657536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK4080","BK4231"],"gpt_icon":0},{"id":"1195658704","title":"ADC Therapeutics 2025财年Q3业绩会总结及问答精华：ZENLATA临床进展与市场扩展潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1195658704","media":"业绩会速递","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195658704?lang=zh_cn&edition=full","pubTime":"2025-11-10 22:21","pubTimestamp":1762784502,"startTime":"0","endTime":"0","summary":"ADC Therapeutics管理层强调ZENLATA在第三线以上DLBCL患者中的差异化治疗选择，并持续推进关键试验数据。管理层计划在2026年公布LOTUS V试验的顶线结果，并在2027年进行补充BLA提交。问题3：ZENLATA是否考虑进入DLBCL的一线治疗？ADC Therapeutics在2025财年第三季度通过降低运营成本和私募融资延长现金流，继续推进ZENLATA的临床试验和市场扩展。管理层对未来的市场潜力持乐观态度，预计ZENLATA将在DLBCL的第二线及以上治疗中实现显著的收入增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","ADCT"],"gpt_icon":0},{"id":"2582848995","title":"【券商聚焦】中泰国际重申信达生物(01801)“买入”评级 指武田加盟将夯实公司在IO与ADC领域研发能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2582848995","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582848995?lang=zh_cn&edition=full","pubTime":"2025-11-10 10:54","pubTimestamp":1762743250,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际研报指，信达生物 第三季度的产品销售收入同比增加40%以上至超33亿元人民币，略超预期。虽然肿瘤药达伯舒的第三季度销售额同比减少5.6%至1.4亿美元，但是由于新产品信尔美、信必乐与信必敏快速放量，除达伯舒以外的其他产品销售收入同比增加约八成。该机构指，公司日前与武田药品达成海外授权协议，将共同致力于肿瘤免疫疗法及抗体偶联物的研发。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1969294","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","ADC"],"gpt_icon":0},{"id":"2582862418","title":"吉利德：Trop2 ADC一线治疗HR+/HER2-乳腺三期临床失败","url":"https://stock-news.laohu8.com/highlight/detail?id=2582862418","media":"医药笔记","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582862418?lang=zh_cn&edition=full","pubTime":"2025-11-08 09:31","pubTimestamp":1762565499,"startTime":"0","endTime":"0","summary":"▎Armstrong2025年11月7日，吉利德宣布Trop2 ADC新药Trodelvy对比化疗一线治疗内分泌治疗后HR+/HER2-乳腺癌的三期临床ASCENT-07没有达到PFS主要终点，关键次要终点OS尚未成熟，但观察到获益趋势，研究将继续进行以评估OS数据。Trodelvy一线治疗三阴乳腺癌已经递交上市申请。总结吉利德Trodelvy为全球首款Trop2 ADC，但作为上一代ADC在适应症拓展的道路上充满曲折，先后在非小细胞肺癌、尿路上皮癌失败，此次HR+/HER2-乳腺癌又错失PFS终点，仅守住三阴乳腺癌这一阵地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108093356a6e9fd53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108093356a6e9fd53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","BK4583","LU1674673691.USD","LU2468319806.SGD","LU1430594728.SGD","BK4231","LU2089984988.USD","ADC","BK4566","LU2087621335.USD","IE00B7SZLL34.SGD","LU0109394709.USD","LU0058720904.USD","BK4203","SG9999015978.USD","IE00B19Z3581.USD","BK4532","IE00BZ1G4Q59.USD","IE00B19Z3B42.SGD","LU0234570918.USD","LU1585245621.USD","LU1571399168.USD","LU1066051498.USD","LU2324357040.USD","BK4585","IE0002270589.USD","LU0889565916.HKD","BK4588","LU1066053197.SGD","LU1839511570.USD","BK4550","BK4080","IE00BSNM7G36.USD","LU0882574055.USD","IE00B3T34201.USD","BK4139","LU1674673428.USD","LU0289739699.SGD","HR","BK4225","SG9999015986.USD","BK4578","IE00BKVL7J92.USD","LU0114720955.EUR","LU0823416689.USD","LU1778281490.HKD","SG9999015945.SGD","GILD","SG9999015952.SGD","BK4568"],"gpt_icon":0},{"id":"2581038400","title":"复宏汉霖PD-L1 ADC肺癌新药发布关键数据，CEO朱俊：定位PD-1 联用的super ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2581038400","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581038400?lang=zh_cn&edition=full","pubTime":"2025-11-06 10:36","pubTimestamp":1762396614,"startTime":"0","endTime":"0","summary":"近日，HLX43肺癌关键数据更新发布，首次合并NSCLC II期国际多中心临床研究结果，全球临床价值持续验证。他表示，复宏汉霖至少会开8个III期临床项目，预计会包括两个一线，四个二线，以及两个三线，而这8个III期临床都会集中在肺癌。业内认为，复宏汉霖估值上行的关键在于其自研PD-L1抗体偶联药物HLX43的全球潜力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1762338933079134283","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["PD","02696","BK1161","BK4023","BK4080","BK4231","LU1169589451.USD","ADC","LU1169590202.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.agreerealty.com","stockEarnings":[{"period":"1week","weight":-0.0291},{"period":"1month","weight":-0.0217},{"period":"3month","weight":-0.0185},{"period":"6month","weight":-0.0376},{"period":"1year","weight":-0.0257},{"period":"ytd","weight":0.0185}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Agree Realty Corporation成立于1971年，是马里兰州的一家公司。该公司是一家完全整合的房地产投资信托基金，主要专注于净出租给行业领先租户的零售物业的所有权、收购、开发和管理。","yearOnYearQuotes":[{"month":1,"riseRate":0.580645,"avgChangeRate":-0.003784},{"month":2,"riseRate":0.451613,"avgChangeRate":-0.001428},{"month":3,"riseRate":0.580645,"avgChangeRate":0.015289},{"month":4,"riseRate":0.580645,"avgChangeRate":0.002795},{"month":5,"riseRate":0.5,"avgChangeRate":0.015633},{"month":6,"riseRate":0.65625,"avgChangeRate":0.010123},{"month":7,"riseRate":0.65625,"avgChangeRate":0.022845},{"month":8,"riseRate":0.46875,"avgChangeRate":0.002201},{"month":9,"riseRate":0.46875,"avgChangeRate":-0.006321},{"month":10,"riseRate":0.5625,"avgChangeRate":-0.000339},{"month":11,"riseRate":0.65625,"avgChangeRate":0.003584},{"month":12,"riseRate":0.46875,"avgChangeRate":0.009823}],"exchange":"NYSE","name":"艾格里房产","nameEN":"Agree"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾格里房产,ADC,艾格里房产股票,艾格里房产股票老虎,艾格里房产股票老虎国际,艾格里房产行情,艾格里房产股票行情,艾格里房产股价,艾格里房产股市,艾格里房产股票价格,艾格里房产股票交易,艾格里房产股票购买,艾格里房产股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}